Sophia Genetics

Sophia's platform will be used to analyze data from Devyser's hereditary breast cancer and cystic fibrosis testing kits.

Internal benchmarks from the company show that the new technology, to be released next month, predicts variant pathogenicity with 98 percent accuracy.

The firms plan to combine Sophia's DDM software with Multiplicom's molecular diagnostic kits, and sell the solution to European hospitals and laboratories.

The partners will work on alternatives to current data protection methods which they say make healthcare data unusable for analysis, diagnostics.

The partnership will pair Sophia's informatics infrastructure with IDT's panel to provide an NGS-based solution for routine clinical diagnostics.

The companies are combining their respective products to provide a solution that covers genetic testing from sample prep to clinical reports.

The round was led by Belgian billionaire and founder of Omega Pharma Marc Coucke.

Genycell will distribute the Sophia Data Driven Medicine platform as part of a package to laboratories and hospitals in Spain and Portugal.

The deals are expected to broaden the range of NGS tests in both countries and accelerate adoption of the technology. 

Five UK healthcare institutions will use Sophia's Data Driven Medicine Platform, which employs machine learning and algorithms to analyze patients' genomic samples.

Pages

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.